Top ▲
Target not currently curated in GtoImmuPdb
Target id: 1298
Nomenclature: phosphodiesterase 3A
Abbreviated Name: PDE3A
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 6 | 1141 | 12p12.2 | PDE3A | phosphodiesterase 3A | |
Mouse | 6 | 1141 | 6 G2 | Pde3a | phosphodiesterase 3A, cGMP inhibited | |
Rat | 6 | 1141 | 4q44 | Pde3a | phosphodiesterase 3A |
Previous and Unofficial Names ![]() |
CGI-PDE A | phosphodiesterase 3A cGMP inhibited | phosphodiesterase 3A, cGMP-inhibited | phosphodiesterase 3A, cGMP inhibited |
Database Links ![]() |
|
BRENDA | 3.1.4.17 |
CATH/Gene3D | 1.10.1300.10 |
ChEMBL Target | CHEMBL241 (Hs) |
DrugBank Target | Q14432 (Hs) |
Ensembl Gene | ENSG00000172572 (Hs), ENSMUSG00000041741 (Mm), ENSRNOG00000025042 (Rn) |
Entrez Gene | 5139 (Hs), 54611 (Mm), 50678 (Rn) |
Human Protein Atlas | ENSG00000172572 (Hs) |
KEGG Enzyme | 3.1.4.17 |
KEGG Gene | hsa:5139 (Hs), mmu:54611 (Mm), rno:50678 (Rn) |
OMIM | 123805 (Hs) |
Pharos | Q14432 (Hs) |
UniProtKB | Q14432 (Hs), Q9Z0X4 (Mm), Q62865 (Rn) |
Wikipedia | PDE3A (Hs) |
Enzyme Reaction ![]() |
||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibitor Comments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anagrelide is an approved drug inhibitor of PDE3A in platelets. Amrinone (inamrinone) and cilostazol are significantly selective for the PDE3 isozymes over the other PDEs tested [7]. |
1. Allcock RW, Blakli H, Jiang Z, Johnston KA, Morgan KM, Rosair GM, Iwase K, Kohno Y, Adams DR. (2011) Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast. Bioorg. Med. Chem. Lett., 21 (11): 3307-12. [PMID:21530250]
2. Edmondson SD, Mastracchio A, He J, Chung CC, Forrest MJ, Hofsess S, MacIntyre E, Metzger J, O'Connor N, Patel K et al.. (2003) Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors. Bioorg. Med. Chem. Lett., 13 (22): 3983-7. [PMID:14592490]
3. Jones GH, Venuti MC, Alvarez R, Bruno JJ, Berks AH, Prince A. (1987) Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide. J. Med. Chem., 30 (2): 295-303. [PMID:3027338]
4. Martinez GR, Walker KA, Hirschfeld DR, Bruno JJ, Yang DS, Maloney PJ. (1992) 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J. Med. Chem., 35 (4): 620-8. [PMID:1311763]
5. Meanwell NA, Pearce BC, Roth HR, Smith EC, Wedding DL, Wright JJ, Buchanan JO, Baryla UM, Gamberdella M, Gillespie E et al.. (1992) Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains. J. Med. Chem., 35 (14): 2672-87. [PMID:1321910]
6. Sircar I, Steffen RP, Bobowski G, Burke SE, Newton RS, Weishaar RE, Bristol JA, Evans DB. (1989) Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure. J. Med. Chem., 32 (2): 342-50. [PMID:2536438]
7. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H. (2000) Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem. Pharmacol., 59 (4): 347-56. [PMID:10644042]
8. Venuti MC, Jones GH, Alvarez R, Bruno JJ. (1987) Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856). J. Med. Chem., 30 (2): 303-18. [PMID:3027339]